Table 2.
Univariate Cox proportional hazards regression analysis for metastasis-free survival in 186 patients treated with EBRT combined with BT boost and ADT for localized prostate cancer
| Level | Parameter estimate | HR (95% CI) | p-value | |
|---|---|---|---|---|
| Patient age (years) | –0.010 | 0.99 (0.93-1.06) | 0.752 | |
| BT fractions | 1 vs. 2 | 0.232 | 1.26 (0.46-3.44) | 0.650 |
| ECOG | 1 vs. 0 | 0.833 | 2.30 (0.29-17.94) | 0.427 |
| Nodal irradiation | Yes vs. No | 0.059 | 1.06 (0.36-3.11) | 0.914 |
| TNM | > T1c vs. T1c | 1.267 | 3.55 (0.84-15.02) | 0.085 |
| Gleason grade group | 3/4 vs. 1/2 | 0.439 | 1.55 (0.45-5.32) | 0.484 |
| 5 vs. 1/2 | 1.529 | 4.61 (1.81-11.73) | 0.001 | |
| BED (Gy) | –0.007 | 0.99 (0.96-1.02) | 0.618 | |
| Maximum PSA (ng/ml) | –0.009 | 0.99 (0.97-1.01) | 0.388 | |
| nPSA (10 ng/ml) | 0.087 | 1.09 (1.05-1.13) | < 0.001 | |
| Time to nPSA (days) | 0.0002 | 1.00 (0.99-1.00) | 0.701 | |
| Adjuvant ADT | Yes vs. No | 0.0556 | 1.06 (0.45-2.46) | 0.897 |
| ADT duration (months) | –0.053 | 0.94 (0.80-1.11) | 0.524 | |
| TURP | Yes vs. No | 0.495 | 1.64 (0.22-12.14) | 0.628 |
| PSA bounce (time-varying) | Yes vs. No | –1.505 | 0.20 (0.03-1.65) | 0.142 |
BT – brachytherapy; ECOG – the Eastern Cooperative Oncology Group score; Gleason grade group – International Society of Urological Pathology 2014 grade group system; BED – biologically effective dose; nPSA – PSA nadir; ADT – androgen deprivation therapy; TURP – transurethral resection of the prostate